The keynote speaker for the three-day meeting in Orlando is Sampson Davis, M.D., an emergency medicine physician in New Jersey, an inspirational speaker and co-author of three best-selling books.
Federal legislation affecting pharmacy benefit managers (PBM), specialty pharmacy trends, biosimilars, cellular and gene therapy and health plan perspectives on PBMs are among the topics that will be featured at the Pharmacy Benefit Management Institute Annual National Conference that starts today in Orlando.
The keynote speaker for the three-day meeting is Sampson Davis, M.D., an emergency medicine physician in New Jersey, an inspirational speaker and co-author of three best-selling books. His inspiring story of growing up in Newark, N.J., and excelling academically and as a physician has attracted national attention. He has appeared on many television shows, including “Oprah,” “The Today Show” and “The View.”
Other featured speakers at the meeting include Doug Long, vice president of industry relations at IQVIA; Mike Baldzicki, chief commercial officer, Premier Pharmacy Services; Corey Coleman, vice president of health equity and strategic partnerships at Optum; Ann O’Brien, vice president of consultant relations at Prime Therapeutics; Jennifer Bartley, Pharm.D., M.S., MBA, director, product and innovation, at CVS Health; and Ellen Feeney, Pharm.D., director clinical pharmacy strategies at Highmark.
The meeting attracts attendees from payer and provider sectors, as well as executives and managers at PBMs. Managed Healthcare Executive is the official publication for the meeting.
In addition to Davis’ keynote, the sessions today include discussions of trends and opportunities in care management and an update on legislative and regulatory actions affecting PBMs.
Tomorrow starts with a session on PBMs and health plans on advancing health equity that Coleman is participating in. Other topics on the agenda include nonprescription digital therapeutics, medication adherence, and the ultra-rare orphan drug market.
Biosimilars, chronic disease, gene therapies and oncology specialty drug management are among the topics that Friday’s sessions will cover.